ACIU Historical Financial Ratios

ACIU Stock

USD 3.40 0.01 0.29%

AC Immune is presently reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.11 or Days Sales Outstanding of 390 will help investors to properly organize and evaluate AC Immune financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

About ACIU Financial Ratios Analysis

AC ImmuneFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate AC Immune investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ACIU financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across AC Immune history.

AC Immune Financial Ratios Chart

At this time, AC Immune's Current Ratio is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 1.57 in 2024, whereas Free Cash Flow Yield is likely to drop (0.18) in 2024.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Book Value Per Share Capex To Depreciation Ev To Sales

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing AC Immune stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on AC Immune sales, a figure that is much harder to manipulate than other AC Immune multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most ratios from AC Immune's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Current Ratio is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 1.57 in 2024, whereas Free Cash Flow Yield is likely to drop (0.18) in 2024.

	2021	2023	2024 (projected)
Days Sales Outstanding	74.21	371.04	389.59
PTB Ratio	1.46	2.22	2.11

Days Sales Outstanding Ptb Ratio

AC Immune fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.67	0.53	-0.54	-0.04	-0.47	0.01	0.67	0.97	-0.46	-0.73	0.36	-0.36	-0.04	-0.49	-0.2	0.19	-0.47	-0.14	0.51	-0.04	-0.18	0.12	0.28	-0.73	-0.18
Ptb Ratio	0.67		0.55	-0.83	0.3	-0.08	-0.23	1.0	0.82	-0.06	-0.95	0.73	0.17	0.23	-0.26	-0.26	-0.42	-0.73	-0.17	0.91	0.23	-0.22	0.29	0.39	-0.95	-0.26
Days Sales Outstanding	0.53	0.55		-0.68	-0.02	-0.44	-0.49	0.55	0.59	-0.42	-0.53	0.25	-0.15	0.0	-0.35	0.52	-0.28	-0.72	-0.05	0.54	0.29	-0.11	0.01	-0.1	-0.54	-0.14
Book Value Per Share	-0.54	-0.83	-0.68		-0.16	0.11	0.37	-0.83	-0.7	0.09	0.71	-0.68	-0.17	-0.47	0.52	0.03	0.47	0.97	0.14	-0.88	-0.25	0.19	-0.38	-0.13	0.71	0.24
Free Cash Flow Yield	-0.04	0.3	-0.02	-0.16		0.72	0.31	0.3	0.05	0.72	-0.11	0.52	0.77	0.3	0.21	-0.25	-0.74	0.0	-0.22	0.4	0.02	-0.22	0.45	0.1	-0.11	-0.25
Operating Cash Flow Per Share	-0.47	-0.08	-0.44	0.11	0.72		0.15	-0.08	-0.37	1.0	0.24	0.21	0.91	0.53	0.52	-0.26	-0.55	0.21	0.1	0.07	0.2	0.13	0.26	0.19	0.25	0.1
Capex To Depreciation	0.01	-0.23	-0.49	0.37	0.31	0.15		-0.23	-0.07	0.14	0.19	0.14	0.01	-0.25	-0.06	-0.36	0.05	0.47	-0.6	-0.3	-0.83	-0.57	0.33	-0.01	0.19	-0.53
Pb Ratio	0.67	1.0	0.55	-0.83	0.3	-0.08	-0.23		0.82	-0.06	-0.95	0.73	0.17	0.23	-0.26	-0.26	-0.42	-0.73	-0.17	0.91	0.23	-0.22	0.29	0.39	-0.95	-0.26
Ev To Sales	0.97	0.82	0.59	-0.7	0.05	-0.37	-0.07	0.82		-0.37	-0.84	0.5	-0.21	0.07	-0.47	-0.21	0.02	-0.63	-0.16	0.69	0.04	-0.21	0.19	0.31	-0.84	-0.23
Free Cash Flow Per Share	-0.46	-0.06	-0.42	0.09	0.72	1.0	0.14	-0.06	-0.37		0.23	0.22	0.92	0.54	0.52	-0.25	-0.56	0.19	0.09	0.08	0.21	0.13	0.27	0.19	0.24	0.1
Roic	-0.73	-0.95	-0.53	0.71	-0.11	0.24	0.19	-0.95	-0.84	0.23		-0.57	0.06	-0.09	0.27	0.17	0.24	0.62	0.12	-0.74	-0.16	0.15	-0.14	-0.54	1.0	0.18
Inventory Turnover	0.36	0.73	0.25	-0.68	0.52	0.21	0.14	0.73	0.5	0.22	-0.57		0.45	0.42	-0.35	-0.44	-0.59	-0.56	-0.65	0.82	-0.21	-0.68	0.82	0.05	-0.56	-0.71
Net Income Per Share	-0.36	0.17	-0.15	-0.17	0.77	0.91	0.01	0.17	-0.21	0.92	0.06	0.45		0.49	0.47	-0.26	-0.73	-0.07	-0.07	0.38	0.27	-0.06	0.36	0.0	0.07	-0.11
Days Of Inventory On Hand	-0.04	0.23	0.0	-0.47	0.3	0.53	-0.25	0.23	0.07	0.54	-0.09	0.42	0.49		-0.29	-0.07	-0.42	-0.45	0.1	0.36	0.21	0.11	0.56	0.32	-0.07	0.09
Payables Turnover	-0.49	-0.26	-0.35	0.52	0.21	0.52	-0.06	-0.26	-0.47	0.52	0.27	-0.35	0.47	-0.29		-0.04	-0.07	0.54	0.35	-0.26	0.41	0.37	-0.51	0.03	0.26	0.35
Average Inventory	-0.2	-0.26	0.52	0.03	-0.25	-0.26	-0.36	-0.26	-0.21	-0.25	0.17	-0.44	-0.26	-0.07	-0.04		-0.11	-0.07	0.19	-0.33	0.13	0.2	-0.29	-0.07	0.16	0.22
Capex To Revenue	0.19	-0.42	-0.28	0.47	-0.74	-0.55	0.05	-0.42	0.02	-0.56	0.24	-0.59	-0.73	-0.42	-0.07	-0.11		0.35	0.25	-0.51	-0.14	0.26	-0.46	-0.08	0.24	0.29
Cash Per Share	-0.47	-0.73	-0.72	0.97	0.0	0.21	0.47	-0.73	-0.63	0.19	0.62	-0.56	-0.07	-0.45	0.54	-0.07	0.35		0.09	-0.81	-0.28	0.14	-0.3	-0.03	0.62	0.19
Pocfratio	-0.14	-0.17	-0.05	0.14	-0.22	0.1	-0.6	-0.17	-0.16	0.09	0.12	-0.65	-0.07	0.1	0.35	0.19	0.25	0.09		-0.22	0.8	1.0	-0.74	0.31	0.11	0.99
Interest Coverage	0.51	0.91	0.54	-0.88	0.4	0.07	-0.3	0.91	0.69	0.08	-0.74	0.82	0.38	0.36	-0.26	-0.33	-0.51	-0.81	-0.22		0.29	-0.27	0.43	0.07	-0.73	-0.33
Capex To Operating Cash Flow	-0.04	0.23	0.29	-0.25	0.02	0.2	-0.83	0.23	0.04	0.21	-0.16	-0.21	0.27	0.21	0.41	0.13	-0.14	-0.28	0.8	0.29		0.77	-0.51	0.15	-0.16	0.72
Pfcf Ratio	-0.18	-0.22	-0.11	0.19	-0.22	0.13	-0.57	-0.22	-0.21	0.13	0.15	-0.68	-0.06	0.11	0.37	0.2	0.26	0.14	1.0	-0.27	0.77		-0.73	0.33	0.15	1.0
Days Payables Outstanding	0.12	0.29	0.01	-0.38	0.45	0.26	0.33	0.29	0.19	0.27	-0.14	0.82	0.36	0.56	-0.51	-0.29	-0.46	-0.3	-0.74	0.43	-0.51	-0.73		-0.07	-0.12	-0.73
Income Quality	0.28	0.39	-0.1	-0.13	0.1	0.19	-0.01	0.39	0.31	0.19	-0.54	0.05	0.0	0.32	0.03	-0.07	-0.08	-0.03	0.31	0.07	0.15	0.33	-0.07		-0.54	0.34
Roe	-0.73	-0.95	-0.54	0.71	-0.11	0.25	0.19	-0.95	-0.84	0.24	1.0	-0.56	0.07	-0.07	0.26	0.16	0.24	0.62	0.11	-0.73	-0.16	0.15	-0.12	-0.54		0.18
Ev To Operating Cash Flow	-0.18	-0.26	-0.14	0.24	-0.25	0.1	-0.53	-0.26	-0.23	0.1	0.18	-0.71	-0.11	0.09	0.35	0.22	0.29	0.19	0.99	-0.33	0.72	1.0	-0.73	0.34	0.18

Click cells to compare fundamentals

AC Immune Account Relationship Matchups

High Positive Relationship

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Roe	+ 1.0	Roic
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio
Ev To Operating Cash Flow	+ 0.99	Pocfratio

High Negative Relationship

Roe	- 0.95	Pb Ratio
Roic	- 0.95	Pb Ratio
Roe	- 0.95	Ptb Ratio
Roic	- 0.95	Ptb Ratio
Interest Coverage	- 0.88	Book Value Per Share
Roe	- 0.84	Ev To Sales

AC Immune fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	79.92	5.24	21.33	40.03	24.06	38.71
Ptb Ratio	2.14	1.53	1.46	0.93	2.22	2.11
Days Sales Outstanding	208.12	3.6	37.63	74.21	371.04	389.59
Book Value Per Share	3.86	3.0	3.1	2.02	1.9	1.7
Free Cash Flow Yield	0.0917	(0.19)	(0.2)	(0.47)	(0.17)	(0.18)
Operating Cash Flow Per Share	(0.39)	(0.71)	0.78	(0.83)	(0.88)	(0.75)
Stock Based Compensation To Revenue	0.35	0.0255	0.26	0.85	0.29	0.16
Capex To Depreciation	1.11	0.87	1.1	0.53	0.36	0.34
Pb Ratio	2.14	1.53	1.46	0.93	2.22	2.11
Ev To Sales	58.24	3.52	11.05	32.72	18.99	31.88
Free Cash Flow Per Share	0.76	(0.85)	(0.91)	(0.9)	(0.72)	(0.76)
Roic	0.16	(0.29)	(0.34)	(0.42)	(0.33)	(0.35)
Net Income Per Share	0.64	(0.86)	(0.97)	(0.85)	(0.64)	(0.67)
Payables Turnover	355.15	27.24	31.09	64.95	32.52	43.9
Sales General And Administrative To Revenue	1.05	0.0849	0.72	4.01	0.71	0.61
Research And Ddevelopement To Revenue	6.15	0.45	3.86	15.33	3.69	2.82
Capex To Revenue	0.26	0.017	0.11	0.31	0.0541	0.0738
Cash Per Share	4.09	3.14	2.64	1.47	1.22	1.64
Pocfratio	10.54	(5.53)	(5.15)	(2.14)	(5.89)	(6.19)
Interest Coverage	23.51	(332.93)	(135.99)	(199.57)	(304.68)	(289.45)
Capex To Operating Cash Flow	0.0341	(0.0287)	(0.0401)	(0.0168)	(0.0133)	(0.0139)
Pfcf Ratio	10.91	(5.38)	(4.95)	(2.11)	(5.82)	(6.11)
Days Payables Outstanding	1.03	13.4	11.74	5.62	11.22	10.66
Income Quality	1.22	0.96	0.9	1.04	1.11	0.73
Ev To Operating Cash Flow	7.08	(2.87)	(3.94)	(1.75)	(4.65)	(4.89)
Pe Ratio	12.8	(5.3)	(4.63)	(2.23)	(6.56)	(6.89)
Ev To Free Cash Flow	7.33	(2.79)	(3.79)	(1.72)	(4.59)	(4.82)
Earnings Yield	0.0781	(0.19)	(0.22)	(0.45)	(0.15)	(0.16)
Net Debt To E B I T D A	(4.28)	2.59	1.03	0.42	1.45	2.88
Current Ratio	16.72	16.53	10.12	11.16	9.22	9.35
Tangible Book Value Per Share	3.86	3.0	2.42	1.42	1.3	1.57
Receivables Turnover	1.75	101.39	9.7	4.92	0.98	0.93
Graham Number	7.48	7.63	8.24	6.21	5.23	4.01
Shareholders Equity Per Share	3.86	3.0	3.1	2.02	1.9	1.7
Capex Per Share	0.0267	0.0237	0.0352	0.0148	0.009458	0.0147

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

ACIU Historical Financial Ratios

About ACIU Financial Ratios Analysis

AC Immune Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Book Value Per Share

Capex To Depreciation

Ev To Sales

AC Immune fundamentals Correlations

AC Immune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AC Immune fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for ACIU Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY